Trending: FTC Ends Challenge of Amgen/Horizon Deal
2023年9月2日 - 3:46AM
Dow Jones News
14:16 ET -- Amgen and Horizon Therapeutics are among the most
mentioned companies in the U.S. across all news items in the last
12 hours, according to Factiva data. The Federal Trade Commission
agreed to end its legal challenge of Amgen's $27.8 billion deal to
buy Horizon. The pact also dismisses the antitrust claims of six
states that joined the FTC seeking to block the transaction over
concerns that Amgen would illegally bundle its products with
Horizon's medicines for thyroid eye disease and gout. The companies
expect to close the deal early in the fourth quarter. Dow Jones
& Co. owns Factiva. (josh.beckerman@wsj.com)
(END) Dow Jones Newswires
September 01, 2023 14:31 ET (18:31 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Horizon Therapeutics Pub... (NASDAQ:HZNP)
過去 株価チャート
から 5 2024 まで 6 2024
Horizon Therapeutics Pub... (NASDAQ:HZNP)
過去 株価チャート
から 6 2023 まで 6 2024
